Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276702 · ClinicalTrials.gov registry record
Tumor Rebiopsy in Children and Adolescents With Recurrent or Progressive Solid Malignancies
A clinical trial of Tumor, Solid, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT03276702: Completed study of Tumor, Solid, sponsored by St. Jude Children's Research Hospital.
NCT03276702 is a study of Tumor, Solid that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 8 participants, below the 243-participant average among 11 other Tumor, Solid trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03276702, a study of Tumor, Solid, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
It has been shown that the genomic landscape of tumors can dramatically change at the time of disease progression. This suggests that therapies aimed at treating the tumor at diagnosis may not be relevant at the time of relapse. Obtaining fresh tissue at the time of relapse could facilitate the identification of potential targets that have developed through mutational evolution of the primary tumor and would provide an unprecedented opportunity to expand the library of patient derived xenografts (PDX) that are available for comprehensive preclinical testing in the setting of relapsed disease. The purpose of this observational study is to prospectively collect fresh tumor tissue from pediatric patients with solid tumors who have recurrent or progressive disease and submit this tissue for comprehensive genomic analysis using clinically available CLIA-certified platforms that include WGS, WES and RNAseq, and to assess the reasons for a patient and/or a parent for making a decision to proceed with or refuse a re-biopsy procedure in the presence of a recurrent or progressive solid tumor. The data obtained will be used to develop new novel therapies that incorporate new pharmacological agents in pediatric solid tumors. PRIMARY OBJECTIVES: * To prospectively collect fresh tumor tissue from pediatric patients with solid tumors who have recurrent or progressive disease and submit this tissue for comprehensive genomic analysis. * To assess the reasons a patient and/or a parent make the decision to proceed with or refuse a re-biopsy procedure in the presence of a recurrent or progressive solid tumor. SECONDARY OBJECTIVES: * To estimate refusal and acceptance rates for re-biopsy and the parental/patient attitudes towards a re-biopsy. * To estimate the incidence of complications associated with biopsy. * To estimate the percentage of procedures that fail to obtain adequate tissue for genomic analysis.
Primary Outcome
Good quality of the sampled tumor is defined as greater than 50% viable tumor from which at least 2 µg DNA and 1 µg RNA can be extracted.
Conditions Studied
Interventions
- OTHER Questionnaire
- PROCEDURE Re-biopsy
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2019-07-31 |
What the finished NCT03276702 record still lists
NCT03276702 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 243-participant average among 11 other Tumor, Solid trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Tumor, Solid appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire is the first listed.
NCT03276702 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03276702 about?
NCT03276702 is a clinical study titled "Tumor Rebiopsy in Children and Adolescents With Recurrent or Progressive Solid Malignancies". It has been shown that the genomic landscape of tumors can dramatically change at the time of disease progression. This suggests that therapies aimed at treating the tumor at diagnosis may not be relevant at the time of relapse. Obtaining fresh tissue at the time of relapse could facilitate the iden...
What is the current status of trial NCT03276702?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2017-12-13. Estimated completion is 2019-07-31.
What conditions does trial NCT03276702 study?
This clinical trial studies the following conditions: Tumor, Solid.
What interventions are being tested in trial NCT03276702?
The interventions under investigation include: Questionnaire (OTHER), Re-biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03276702?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03276702 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor, Solid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03276702's enrollment target sits among peer trials
8 12th of 11 the lowest of 11 other Tumor, Solid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumor, Solid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
TumorGlow Intraoperative Molecular Imaging (IMI)
RECRUITING · Phase 1
-
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
RECRUITING · Phase 1
-
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
RECRUITING · Phase 1
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI